GLP-1 Side Effects: Ozempic, Wegovy & Tirzepatide Guide (2026)

01

The most common GLP-1 side effects (gastrointestinal)

In placebo-controlled trials of semaglutide, gastrointestinal reactions were the most frequently reported, and they were clearly dose-related.

According to the FDA-approved Ozempic label, the reactions occurring in ≥5% of patients were nausea, vomiting, diarrhea, abdominal pain, and constipation.

The label reports the following incidence versus placebo:

Crucially, the label notes that most reports of nausea, vomiting, and diarrhea occurred during dose escalation — the period when your dose is being stepped up.

For tirzepatide the pattern is similar; nausea was reported by up to about 18% of people taking Mounjaro (diabetes) and up to about 29% taking Zepbound (weight loss), per manufacturer and clinical data, along with burping, heartburn, and gas.

Nausea

Nausea is the single most common complaint. It typically peaks in the first one to three days after a dose or a dose increase, then settles.

Practical strategies widely recommended by clinics: eat smaller, more frequent meals, eat slowly and stop at the first feeling of fullness, favor bland, low-fat foods, and sip fluids between meals rather than with them. If nausea is disruptive, some clinicians prescribe a short course of an anti-nausea medicine such as ondansetron around dose increases. (See our deep-dive: How to Manage GLP-1 Nausea.)

Vomiting and diarrhea

Vomiting and diarrhea are less common than nausea but can cause a real problem: dehydration. Because these drugs can also reduce your thirst and appetite, it's easy to under-drink.

Persistent vomiting or diarrhea that keeps you from holding down fluids is a reason to call your clinician, partly because dehydration can rarely trigger acute kidney injury (see serious effects below).

Constipation

Constipation is common and stems from slowed gut motility. Standard measures — more fiber, adequate fluids, and regular movement — usually help.

Persistent constipation with severe cramping, bloating, and vomiting, however, can signal a bowel obstruction and should be evaluated. (Deep-dive: GLP-1 Constipation Relief.)

Other common effects

People also report burping, heartburn, gas, fatigue, headache, dizziness, and injection-site reactions (redness or itching at the injection spot).

Hair thinning is sometimes reported, but this is generally attributed to rapid weight loss rather than a direct drug effect, and it is usually temporary.

02

How long do GLP-1 side effects last?

For most people, the common GI side effects are temporary. Nausea and related symptoms most often improve within about 2 to 4 weeks of starting the medication or of each dose increase, as your body adjusts.

Because side effects cluster around dose changes, a slow, gradual dose escalation is the single most effective way to limit them — which is exactly why the manufacturers build in a multi-week titration schedule.

If a side effect is still severe after four weeks, or you're losing weight faster than intended, that's a signal to talk with your prescriber.

They may hold your dose at the current step longer or reduce it. Do not adjust your own dose without medical guidance.

03

Serious GLP-1 side effects and warnings

These are less common but important. They are the reason GLP-1 drugs are prescription-only and require medical supervision.

Pancreatitis (inflammation of the pancreas)

FDA labeling warns that acute pancreatitis has occurred in clinical trials.

The classic sign is severe, persistent abdominal pain — often in the upper abdomen and sometimes radiating to the back — with or without vomiting.

Manufacturer guidance is explicit: stop the medication and seek care promptly if this happens. If pancreatitis is confirmed, the drug should not be restarted.

Gallbladder problems and gallstones

The labels warn of gallbladder disease, including gallstones (cholelithiasis), some of which may require surgery.

Notably, the FDA has stated the incidence of acute gallbladder disease was higher with semaglutide than placebo even after accounting for the degree of weight loss. Warning signs include pain in the upper-right abdomen, fever, yellowing of the skin or eyes (jaundice), and clay-colored stools.

Delayed gastric emptying and gastroparesis

GLP-1 drugs slow stomach emptying by design, but in some people this becomes problematic.

The FDA has added delayed gastric emptying to semaglutide labeling, and the Ozempic label was updated to note it is not recommended in patients with severe gastroparesis. Postmarketing reports also list ileus (intestinal blockage). A related concern is a rare risk of pulmonary aspiration during anesthesia because food may remain in the stomach — which is why many clinicians ask whether you take a GLP-1 before surgery or certain procedures.

Tell your care team about your GLP-1 use ahead of any planned sedation.

Boxed warning: thyroid C-cell tumors

Both semaglutide (Ozempic, Wegovy) and tirzepatide carry the FDA's strongest boxed warning for thyroid C-cell tumors, based on findings in rodents given the drugs over their lifetime.

Whether this risk applies to humans is not known. Because of it, these drugs are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report symptoms such as a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Hypoglycemia (low blood sugar)

On their own, GLP-1 drugs carry a low risk of hypoglycemia, but the risk rises sharply when combined with insulin or a sulfonylurea. If you take those, your clinician may adjust their doses.

Know the symptoms: shakiness, sweating, confusion, rapid heartbeat, and dizziness.

Acute kidney injury

Severe vomiting, diarrhea, or dehydration can, in rare cases, lead to acute kidney injury, sometimes worsening pre-existing kidney disease.

Staying hydrated and reporting persistent GI symptoms early helps prevent this.

Other labeled risks

Labels also mention hypersensitivity/allergic reactions, diabetic retinopathy complications (in people with type 2 diabetes — get recommended eye monitoring), and a modest increase in heart rate.

A note on suicidal thoughts

Early reports raised a question about suicidal thoughts.

After formal reviews, the U.S. FDA (2024) and the European Medicines Agency's PRAC (April 2024) concluded that the available evidence does not support a causal link between GLP-1 receptor agonists and suicidal or self-harm thoughts, and the FDA subsequently requested removal of that specific warning.

As always, if you experience new or worsening mood changes, contact your clinician.

04

When to seek care: GLP-1 red-flag table

This table is a guide, not a substitute for professional judgment. When in doubt, call your clinician or emergency services.

05

Do side effects differ by drug? A comparison overview

All GLP-1-based drugs share the same broad side-effect profile, but there are differences in degree and in labeling.

This table is a general overview — individual experience varies widely.

Some evidence suggests tirzepatide may produce more GI complaints at higher weight-loss doses, but head-to-head tolerability varies by person and dose.

The most reliable predictor of side effects is how quickly you escalate the dose, not which brand you choose. *(Deep-dive: [Ozempic vs. Wegovy vs.

Zepbound](/en/semaglutide-vs-tirzepatide).)*

06

Practical ways to reduce side effects

1. Go slow. Follow the titration schedule; don't rush to a higher dose.
2. Eat smaller, more frequent, lower-fat meals and stop at the first sign of fullness.
3. Hydrate — sip water through the day, especially if you have any vomiting or diarrhea.
4. Limit greasy, fried, very sweet, and heavily processed foods, which tend to worsen nausea.
5. Move your body and get fiber to counter constipation.
6. Track your symptoms so you and your clinician can spot patterns and decide on dose timing.
7. Ask about anti-nausea options around dose increases if needed.
8. Report red-flag symptoms immediately — don't "wait it out."

Because side effects cluster around specific days and doses, keeping a simple log of what you feel, when you dosed, and what you ate makes conversations with your clinician far more useful.

This is exactly the kind of thing the Havit app is built to make effortless — log your GLP-1 doses, meals, and how you feel each day, and see your own patterns over time so you can bring real data to your next appointment. (It's a tracking companion, not a medical device — always defer to your clinician.)

07

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

When to seek care: GLP-1 red-flag table

Related articles